Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
4.44
-0.11 (-2.42%)
At close: Aug 22, 2025, 10:10 AM
Acurx Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -10.02M | -11.87M | -14.1M | -16.44M | -16.73M | -16.05M | -14.58M | -12.72M | -13.15M | -12.33M | -12.09M | -11.46M | -12.56M | -14.01M | -12.81M | -11.28M | -7.95M | -4.8M |
Interest Income | 23.4K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -10M | -11.87M | -14.1M | -16.44M | -16.73M | -16.05M | -14.58M | -12.72M | -13.15M | -12.33M | -12.09M | -11.46M | -12.56M | -13.94M | -12.75M | -11.21M | -7.89M | -4.8M |
Net Income | -10M | -11.87M | -14.1M | -16.44M | -16.73M | -16.05M | -14.58M | -12.72M | -13.15M | -12.33M | -12.09M | -11.46M | -12.56M | -13.94M | -12.75M | -11.21M | -7.89M | -4.8M |
Selling & General & Admin | 6.88M | 7.43M | 8.7M | 9.91M | 10.06M | 9.47M | 8.53M | 7.19M | 7.37M | 7.37M | 7.34M | 7.42M | 8.99M | 11.25M | 10.78M | 9.51M | 6.65M | 3.19M |
Research & Development | 3.15M | 4.45M | 5.4M | 6.52M | 6.67M | 6.58M | 6.04M | 5.53M | 5.78M | 4.95M | 4.75M | 4.04M | 3.57M | 2.76M | 2.03M | 1.77M | 1.3M | 1.61M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 10.02M | 11.87M | 14.1M | 16.44M | 16.73M | 16.05M | 14.58M | 12.72M | 13.15M | 12.33M | 12.09M | 11.46M | 12.56M | 14.01M | 12.81M | 11.28M | 7.95M | 4.8M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 10.02M | 11.87M | 14.1M | 16.44M | 16.73M | 16.05M | 14.58M | 12.72M | 13.15M | 12.33M | 12.09M | 11.46M | 12.56M | 14.01M | 12.81M | 11.28M | 7.95M | 4.8M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.19M | 1M | 851.55K | 818.15K | 791.25K | 773.65K | 673.1K | 650.25K | 609.3K | 581.95K | 580.3K | 557.4K | 513.15K | 511.65K | 511.23K | 505.8K | 348.4K | 477.05K |
Shares Outstanding (Diluted) | 1.19M | 1M | 851.55K | 818.15K | 791.25K | 773.65K | 673.1K | 650.25K | 609.3K | 581.95K | 580.3K | 557.4K | 513.15K | 511.65K | 511.23K | 505.8K | 348.4K | 477.05K |
EPS (Basic) | -10.75 | -14.07 | -17.59 | -21.92 | -23.26 | -23.65 | -22.99 | -11.79 | -13.4 | -13 | -13.2 | -22 | -24.8 | -31 | -28.8 | -25.8 | -19.4 | -9.91 |
EPS (Diluted) | -10.75 | -14.07 | -17.59 | -21.92 | -23.26 | -23.65 | -22.99 | -11.79 | -13.4 | -13 | -13.2 | -24.4 | -27.2 | -33.4 | -31.2 | -25.8 | -19.4 | -9.91 |
EBITDA | -10M | -11.87M | -14.1M | -16.44M | -16.73M | -16.05M | -14.58M | -12.72M | -13.15M | -12.33M | -12.09M | -11.46M | -12.56M | -13.94M | -12.75M | -11.21M | -7.89M | -4.8M |
EBIT | -10M | -11.87M | -14.1M | -16.44M | -16.73M | -16.05M | -14.58M | -12.72M | -13.15M | -12.33M | -12.09M | -11.46M | -12.56M | -13.94M | -12.75M | -11.21M | -7.89M | -4.8M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |